A 30-year-old man with major depressive disorder undergoes pharmacogenomic testing that reveals he is a CYP2D6 poor metabolizer. He has no prior medication trials. The PMHNP is selecting an initial antidepressant. Which of the following medications would require the most significant dose adjustment or avoidance based on this metabolizer status?